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EVOLUTION
Clostridium difficile toxin B was detected in the fecal samples of
both episodes and a further course of treatment with oral
metronidazole was administered, with good clinical response.
Colonoscopy was not performed due to megacolon-associated
risk of perforation. Symptoms disappeared rapidly.
Four days after the end of therapy after the second episode,
CD toxin-positive watery diarrhea returned. The patient was
treated for 14 days with oral vancomycin (125 mg every 6 h) and
for replenishment of the normal flora with oral administration
of the yeast Saccharomyces boulardii. He responded to therapy and
no more relapses were documented. The patient received a total
of 50 days of antiviral therapy and was discharged.
DISCUSSION
1. The diagnosis is recurring C. difficile infection. Toxin-pro-
ducing C. difficile has been reported as the etiologic agent of
pseudomembranous colitis and up to 20–25% of cases of
antibiotic-associated diarrhea. Incidence seems to be signifi-
cantly increasing world wide, even taking into account
improved diagnosis and increased awareness [1–6]. The most
important factor in the pathogenesis of disease is exposure to
antibiotics that disturb the homeostasis of the colonic flora.
Nosocomial transmission has also been described [3].
Tissue culture assay is the standard method to test for C.
difficile; neutralisation of toxin cytopathic effect by C. difficile
antitoxin confirms the diagnosis [7].
However, C. difficile-associated diarrhea (CDAD) may pose
important diagnostic problems in the heart transplant setting.
Clinical presentation may be atypical and sometimes quite
severe; differential diagnosis with other entities causing diarrhea
in this population is required (CMV, adenovirus) and relapses
may be difficult to manage. C. difficile colitis may occur, as was
the case in our patient, in conjunction with CMV gastroin-
testinal infection, which may make diagnosis difficult [8].
2. C. difficile is reported to be the main cause of bacterial
diarrhea in immunosuppressed patients although quite fre-
quently may pass undetected [9]. The incidence of CDAD is
increased in solid organ transplant recipients and clinical pre-
sentation may be unusually severe [10]. In our experience,
16.6% of HT recipients suffer C. difficile-associated diarrhea.
Patients had been in the hospital a median of 64 days and the
diagnosis was established 51 days after transplantation. Two
patients (14%) each had three severe relapsing episodes [11].
All patients had received antimicrobials before the episode
(median 2.4 per patient, including prophylactic agents). Liquid
diarrhea was present in all the patients, with a median of 10
movements per day. Other manifestations were abdominal pain
(29%), fever (14%) and gastrointestinal bleeding (14%). Dura-
tion of symptoms was 15 (1–48) days [11].
Heart transplant recipients are susceptible to many risk factors
for developing CDAD: surgery, frequent hospital admissions,
exposure to antimicrobials and immunosuppression.
Although nearly all patients respond to oral vancomycin or
metronidazole [12], 10–20% have a relapse of diarrhea follow-
ing treatment [13,14], and approximately 1% have further
relapses [15].
3. About 15–25% of patients will respond within a few days
to discontinuation of the antibiotic therapy that orginated the
disease. This first step of management may be taken into
consideration in patients with non-severe CDAD whenever
possible.
Non-responding patients or those with severe disease should
be treated with antimicrobials. Metronidazole is the drug of
choice because its activity is similar to that of vancomycin in
patients with moderately severe disease, its reduced risk of
vancomycin resistance induction and its lower cost [3]. When
oral administration is not feasible, IV metronidazole should be
used, because IV vancomycin is not effective. Treatment is
usually administered for 7–10 days, although nearly all patients
respond in about 5 days [12].
A substantial proportion of patients (10–20%) have a relapse,
usually 3–10 days after treatment has been discontinued [13,14],
even with no further antibiotic therapy. Relapse usually results
from either a failure to eradicate C. difficile spores from the colon
or is due to reinfection from the environment [3,16].
Nearly all patients with a second relapse respond to another
course of metronidazole if given early. The frequency of relapses
does not seem to be affected by the antibiotic selected for treat-
ment, the dose of these drugs, or the duration of treatment [3].
Third or multiple relapses should be treated with vancomycin
and with other measures attempting to inhibit the growth and
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toxin production of C. difficile and to allow normal microbial
flora restoration. Gradual tapering of the dosage of vancomycin
over 1–2 months, administration of ‘pulse-dose’ vancomycin,
use of anion-exchange resins to absorb C. difficile toxin A and
administration of vancomycin plus rifampin or immunoglobu-
lins have all been proposed [13,14,17–19].
There have been several reports concerning the treatment
of recurrent colitis by direct reconstitution of the intestinal flora.
This was attempted with oral administration of lactobacilli
and/or the yeast S. boulardii and even by means of rectal
instillation of stool from a healthy donor [20,21]. Nevertheless,
methods to deal effectively with relapses are not standardised.
In our patient, combined oral treatment with vancomycin
and S. boulardii was successful and he had no further relapses
during a 6-month follow-up. Doctors dealing with heart
transplant recipients should be aware of the increasing incidence
of C. difficile diarrhea in this population.
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